CLINICAL_TRIALS
trial_result
· 2012-03-30
Clinical Trial Update: Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer [Phase 2]
Summary
A Phase 2 study of axitinib (AG-013736) in metastatic thyroid neoplasms has completed, with results posted in March 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Thyroid Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2012-03-30